A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Clinical trial NCT02729896 · COMPLETED
Trial details
- NCT number
- NCT02729896
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-11-09
- Primary completion
- 2018-09-03
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.